title: [Chronic lymphatic leukemia. Peroral cladribine as primary treatment].
abstract: Ten patients with newly diagnosed B-chronic lymphocytic leukaemia were treated with cladribin orally for five days every four weeks with a median of four series. This is the first reported clinical study where a purine analogue is administered orally. The tumour reducing effect was fast. Eight out of 10 patients responded with a partial or clinical complete remission. Two of these were in molecular biological complete remission. With an observation time of 22 months we have seen no serious side effects so far. A randomized study (including a long term follow up) between chlorambucil, fludarabin and cladribin is needed to clarify the future role of cladribin in B-CLL treatment.
authors.affiliation: Haematologisk afdeling L, Rigshospitalet, København.
authors.forename: S B
authors.initials: SB
authors.lastname: Gjedde
authors.forename: G
authors.initials: G
authors.lastname: Juliusson
authors.forename: M M
authors.initials: MM
authors.lastname: Hansen
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017338:Cladribine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D000970:Antineoplastic Agents; D017338:Cladribine